A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

NCT05709093 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Company Development strategy adjustment\]

Conditions

Myelodysplastic Syndromes(MDS)

Interventions

DRUG: Lemzoparlimab+Azacitidine (AZA)
DRUG: Azacitidine (AZA)

Sponsor

TJ Biopharma Co., Ltd.